Current Cancer Drug Targets
Volume 22, 11 Issues, 2022
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
Contents
Current Cancer Drug Targets , Volume 10 - Number 7
Bone-Targeted Doxorubicin-Loaded Nanoparticles as a Tool for the Treatment of Skeletal Metastases
, 10(7): 649 - 659M. Salerno, E. Cenni, C. Fotia, S. Avnet, D. Granchi, F. Castelli, D. Micieli, R. Pignatello, M. Capulli, N. Rucci, A. Angelucci, A. Del Fattore, A. Teti, N. Zini, A. Giunti and N. Baldini
DOI: 10.2174/156800910793605767
Oxaliplatin-mediated Inhibition of Survivin Increases Sensitivity of Head and Neck Squamous Cell Carcinoma Cell Lines to Paclitaxel
, 10(7): 660 - 669Z. Khan, N. Khan, A. K. Varma, R. P. Tiwari, S. Mouhamad, G. B.K.S. Prasad and P. S. Bisen
DOI: 10.2174/156800910793605866
The Role of Oxidative Stress and Anti-Oxidant Treatment in Platinum- Induced Peripheral Neurotoxicity
, 10(7): 670 - 682V. A. Carozzi, P. Marmiroli and G. Cavaletti
DOI: 10.2174/156800910793605820
Is Src a Viable Target for Treating Solid Tumours?
, 10(7): 683 - 694B. Elsberger, B. Stewart, O. Tatarov and J. Edwards
DOI: 10.2174/156800910793605802
Modular Branched Neurotensin Peptides for Tumor Target Tracing and Receptor-Mediated Therapy: A Proof-of-Concept
, 10(7): 695 - 704C. Falciani, B. Lelli, J. Brunetti, S. Pileri, A. Cappelli, A. Pini, C. Pagliuca, N. Ravenni, L. Bencini, S. Menichetti, R. Moretti, M. De Prizio, M. Scatizzi and L. Bracci
DOI: 10.2174/156800910793605875
Paclitaxel Efficacy is Increased by Parthenolide via Nuclear Factor- KappaB Pathways in In Vitro and In Vivo Human Non–Small Cell Lung Cancer Models
, 10(7): 705 - 715Z. W. Gao, D. L. Zhang and C. B. Guo
DOI: 10.2174/156800910793605776
Wnt/β-Catenin/LEF-1 Signaling in Chronic Lymphocytic Leukemia (CLL): A Target for Current and Potential Therapeutic Options
, 10(7): 716 - 727R. K. Gandhirajan, S. J. Poll-Wolbeck, I. Gehrke and K.-A. Kreuzer
DOI: 10.2174/156800910793605794
New Insights of CTLA-4 into Its Biological Function in Breast Cancer
, 10(7): 728 - 736H. Mao, L. Zhang, Y. Yang, W. Zuo, Y. Bi, W. Gao, B. Deng, J. Sun, Q. Shao and X. Qu
DOI: 10.2174/156800910793605811
Dynamic Simulations of Pathways Downstream of ERBB-Family, Including Mutations and Treatments: Concordance with Experimental Results
, 10(7): 737 - 757N. Castagnino, L. Tortolina, A. Balbi, R. Pesenti, R. Montagna, A. Ballestrero, D. Soncini, E. Moran, A. Nencioni and S. Parodi
DOI: 10.2174/156800910793605848
DNA Topoisomerase II Enzymes as Molecular Targets for Cancer Chemotherapy
, 10(7): 758 - 771K. Chikamori, A. G. Grozav, T. Kozuki, D. Grabowski, R. Ganapathi and M. K. Ganapathi
DOI: 10.2174/156800910793605785
Concomitant CXCR4 and CXCR7 Expression Predicts Poor Prognosis in Renal Cancer
, 10(7): 772 - 781S. Perdona, S. Scala, G. Castello, S. Costantini, A. Ottaiano, L. Pucci, N. Longo, G. Carteni, G. Facchini, S. Pignata, C. D'Alterio, L. Claudio, L. Marra, R. Calemma, M. Cioffi, L. Portella, L. Cindolo, R. Franco, M. Polimeno and C. Consales
DOI: 10.2174/156800910793605839
Cancer Therapy By Targeting Hypoxia-Inducible Factor-1
, 10(7): 782 - 796Y. Li and D. Ye
DOI: 10.2174/156800910793605857
Editor-in-Chief
Ruiwen Zhang
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204
(USA)
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204
COPE Compliant
About the Journal
⇨ Journal Home⇨ Editorial Policies⇨ Fabricating and Stating False Information⇨ Research Misconduct⇨ Allegations from Whistleblowers⇨ Editorial Board⇨ Meet the Executive Guest Editor(s)⇨ Board Recruitment Workflow⇨ Join Editorial Board⇨ Indexing Information⇨ Announcements⇨ Endorsements⇨ Authors' Comments
For Authors
For Librarians & Readers
Quick Links
Journal History
Current Cancer Drug Targets was launched in 2001. Dr. Ruiwen Zhang serves as the Editor-in-Chief of the journal.
Webmaster Contact: info@benthamscience.net